Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models
Open Access
- 13 February 2024
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 18 (6) , 1552-1570
Abstract
Serine/threonine‐protein kinase B‐raf (BRAF) mutations are found in 8–15% of colorectal cancer patients and identify a subset of tumors with poor outcome in the metastatic setting. We have previously reported that BRAF‐mutant human cells display a high rate of protein production, causing proteotoxic stress, and are selectively sensitive to the proteasome inhibitors bortezomib and carfilzomib. In this work, we tested whether carfilzomib could restrain the growth of BRAF‐mutant colorectal tumors not only by targeting cancer cells directly, but also by promoting an immune‐mediated antitumor response. In human and mouse colorectal cancer cells, carfilzomib triggered robust endoplasmic reticulum stress and autophagy, followed by the emission of immunogenic‐damage‐associated molecules. Intravenous administration of carfilzomib delayed the growth of BRAF‐mutant murine tumors and mobilized the danger‐signal proteins calreticulin and high mobility group box 1 (HMGB1). Analyses of drug‐treated samples revealed increased intratumor recruitment of activated cytotoxic T cells and natural killers, concomitant with the downregulation of forkhead box protein P3 (Foxp3)+ T‐cell surface glycoprotein CD4 (CD4)+ T cells, indicating that carfilzomib promotes reshaping of the immune microenvironment of BRAF‐mutant murine colorectal tumors. These results will inform the design of clinical trials in BRAF‐mutant colorectal cancer patients.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (22795, 21923, 21407, 21744, 21091)
- H2020 European Research Council (101020342)
This publication has 57 references indexed in Scilit:
- Immunogenic Cell Death in Hematological Malignancy TherapyAdvanced Science, 2023
- Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancerCancer Cell, 2023
- The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancerDiscover Oncology, 2022
- Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myelomaCellular and Molecular Life Sciences, 2021
- Autophagy regulates long‐term cross‐presentation by murine dendritic cellsEuropean Journal of Immunology, 2020
- Endoplasmic Reticulum Stress Signaling in Cancer CellsThe American Journal of Pathology, 2020
- Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models2018
- High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFSAnnals of Hematology, 2018
- Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon CancersJAMA Oncology, 2017
- Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted TherapyCurrent Oncology Reports, 2016